Arax Advisory Partners’s Exagen XGN Stock Holding History

Arax Advisory Partners’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97.3K	Hold	20,918	–	–	﹤0.01%	2750
2026 Q1	$62.8K	Buy	+20,918	New	+$80.9K	﹤0.01%	1587

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Arax Advisory Partners's XGN Position: Q2 2026 in Review

Arax Advisory Partners held its Exagen (XGN) position steady in Q2 2026 at 20,918 shares worth $97.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2750.

Arax Advisory Partners first reported a position in XGN in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

Arax Advisory Partners held 20,918 shares of Exagen worth $97.3K as of Q2 2026.
Arax Advisory Partners left its Exagen share count unchanged in Q2 2026.
Exagen made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2750 holding.
Arax Advisory Partners first reported a position in Exagen in Q1 2026 and has held it in 2 quarters since.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.